Kymera Therapeutics, Inc. (KYMR:NASDAQ) closed at $113.46 on October 20, 2026, up 4.99% on the day. The stock trades 12.8% below its 52-week high of $130.05 and 105.3% above its 52-week low of $55.26. Over the past year, it gained 78.6%. Kymera Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 20, 2025, KYMR closed higher on 133 days (53%). Its best day was December 8, 2025 (+41.55%) and its worst was June 2, 2026 (-9.15%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 2 times.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Find more stocks like KYMR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.